Symbols

CODX

Co-diagnostics·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Stock Price Surged Significantly

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CODX

Co-Diagnostics, Inc.

The leading U.S. PCR molecular diagnostics company, specializing in rapid infectious disease nucleic acid testing and precision diagnostic technology R&D

Industry

Healthcare Equipment and Supplies

Established Date

04/18/2013

Listing Date

03/11/2026

Exchange

NASDAQ Stock Exchange

Full-time Employees

132

Fiscal Year Ends

12-31

Website

www.codiagnostics.com

Security Type

Common stock

Office address

2401 S. Foothill Drive, Salt Lake City, Utah 84109

Business

Introduction

Co-diagnostics, Inc., founded on April 18, 2013, is a Utah company headquartered in Salt Lake City, Utah, and is a molecular diagnostic company that has developed and intends to sell molecular diagnostic technologies such as laboratory systems, and manufactures and sells reagents for testing or analytically designed tests using nucleic acid molecules (DNA or RNA).

Company Financials

EPS

CODX has released its 2025 Q3 earnings. EPS was reported at -0.16, versus the expected -0.16, meeting expectations. The chart below visualizes how CODX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CODX has released its 2025 Q4 earnings report, with revenue of 263.92K, reflecting a YoY change of 76.74%, and net profit of -25.75M, showing a YoY change of -133.39%. The Sankey diagram below clearly presents CODX's revenue sources and cost distribution.